MA65713B1 - Procédé de préparation d'aficamten - Google Patents

Procédé de préparation d'aficamten

Info

Publication number
MA65713B1
MA65713B1 MA65713A MA65713A MA65713B1 MA 65713 B1 MA65713 B1 MA 65713B1 MA 65713 A MA65713 A MA 65713A MA 65713 A MA65713 A MA 65713A MA 65713 B1 MA65713 B1 MA 65713B1
Authority
MA
Morocco
Prior art keywords
aficamten
preparation process
inden
oxadiazol
carboxamide
Prior art date
Application number
MA65713A
Other languages
English (en)
Inventor
Matthew PFEIFFER
Bradley P. Morgan
Denise Andersen
Norma TOM
Original Assignee
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Inc. filed Critical Cytokinetics, Inc.
Publication of MA65713B1 publication Critical patent/MA65713B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne un procédé de préparation de (R)-N-(5-(5-éthyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-indèn-1-yl)-1-méthyl-1H-pyrazole-4-carboxamide, d'intermédiaires de celui-ci et de sels correspondants.
MA65713A 2021-08-03 2022-08-02 Procédé de préparation d'aficamten MA65713B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203888P 2021-08-03 2021-08-03
EP22761878.2A EP4380932B1 (fr) 2021-08-03 2022-08-02 Procédé de préparation d'aficamten
PCT/US2022/074427 WO2023015184A1 (fr) 2021-08-03 2022-08-02 Procédé de préparation d'aficamten

Publications (1)

Publication Number Publication Date
MA65713B1 true MA65713B1 (fr) 2026-01-30

Family

ID=83149173

Family Applications (1)

Application Number Title Priority Date Filing Date
MA65713A MA65713B1 (fr) 2021-08-03 2022-08-02 Procédé de préparation d'aficamten

Country Status (15)

Country Link
US (2) US11932631B2 (fr)
EP (1) EP4380932B1 (fr)
JP (1) JP2024530111A (fr)
KR (1) KR20240047360A (fr)
CN (1) CN117813304A (fr)
AR (1) AR126681A1 (fr)
AU (1) AU2022325141A1 (fr)
CA (1) CA3224971A1 (fr)
CL (1) CL2024000264A1 (fr)
HR (1) HRP20251575T1 (fr)
IL (1) IL310592A (fr)
MA (1) MA65713B1 (fr)
MX (1) MX2024001294A (fr)
TW (1) TW202315619A (fr)
WO (1) WO2023015184A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
CN119119018A (zh) * 2019-07-17 2024-12-13 赛特凯恩蒂克公司 多晶型物
IL310140A (en) 2021-07-16 2024-03-01 Cytokinetics Inc Methods for treating hypertrophic cardiomyopathy
US11932631B2 (en) 2021-08-03 2024-03-19 Cytokinetics, Inc. Process for preparing aficamten

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
WO2008002671A2 (fr) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Inhibiteurs des métalloprotéases
AU2007321924A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
CN119119018A (zh) 2019-07-17 2024-12-13 赛特凯恩蒂克公司 多晶型物
GB202102088D0 (en) * 2021-02-15 2021-03-31 Mironid Ltd Compounds and their use as pde4 activators
CN114835687B (zh) 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
US11932631B2 (en) 2021-08-03 2024-03-19 Cytokinetics, Inc. Process for preparing aficamten
CN115093400B (zh) 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂及其用途和制备方法
WO2024134498A1 (fr) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Formes à l'état solide d'aficamten et leur procédé de préparation
WO2024182469A1 (fr) 2023-02-28 2024-09-06 MyoKardia, Inc. Inhibiteurs de myosine destinés à être utilisés dans le traitement de la cardiomyopathie hypertrophique
WO2024179422A1 (fr) 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Co-cristal d'afimten, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
TW202315619A (zh) 2023-04-16
EP4380932C0 (fr) 2025-11-26
EP4380932B1 (fr) 2025-11-26
AU2022325141A1 (en) 2024-02-08
CA3224971A1 (fr) 2023-02-09
IL310592A (en) 2024-04-01
US20230045450A1 (en) 2023-02-09
MX2024001294A (es) 2024-02-13
KR20240047360A (ko) 2024-04-12
EP4380932A1 (fr) 2024-06-12
CL2024000264A1 (es) 2024-08-16
US11932631B2 (en) 2024-03-19
US20240150336A1 (en) 2024-05-09
US12247024B2 (en) 2025-03-11
WO2023015184A1 (fr) 2023-02-09
HRP20251575T1 (hr) 2026-01-30
AR126681A1 (es) 2023-11-01
JP2024530111A (ja) 2024-08-16
CN117813304A (zh) 2024-04-02

Similar Documents

Publication Publication Date Title
MA65713B1 (fr) Procédé de préparation d'aficamten
IL289875A (en) 3. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl- 1h-pyrazole-4-carboxamide
MA54327B1 (fr) Inhibiteurs de kras g12c
UY39571A (es) Oxadiazoles fungicidas y sus mezclas
PE20231013A1 (es) Procesos e intermedios para la preparacion de (s)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1h-pirazol-4-carboxamida
PH12022550083A1 (en) Cardiac sarcomere inhibitor oral formulations
NO20084659L (no) Ko-krystall av C-glucosidderivat og L-prolin
PE20080259A1 (es) Compuestos y metodos para modular fxr
PE20030968A1 (es) Derivados de 5-feniltiazol como inhibidores de cinasas
AR117400A1 (es) Proceso de preparación
ES2398434T8 (es) Isómeros ópticos de un metabolito de iloperidona
CL2011000849A1 (es) Proceso para la preparacion de compuestos derivados de 2-(benceno/heteroaril)-6-(hidroximetil)-piran-3,4,5-triol utiles como inhibidores de sglt.
RU2010146384A (ru) Пирролидиноновые активаторы глюкокиназы
MX2024007907A (es) Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo.
AR119123A1 (es) Procesos e intermediarios para la preparación de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etenona
DE602007001794D1 (de) Verfahren zur herstellung optisch aktiver 5-substituierter 2-oxazolidinone aus racemischen epoxiden und cyanat unter einsatz einer halohydrin-dehalogenase
PE20040591A1 (es) Derivados de oxazol como agonistas de los receptores pparo y/o pparô
PE20011126A1 (es) Formulacion de tabletas de oxazolidinona
MX2022013982A (es) Compuestos de (trifluorometil)pirimidin-2-amina.
NO20070845L (no) Fremgangsmate for fremstilling av losartan
EP3964500A4 (fr) Sel d'un composé diaminopyrimidine, forme solide de celui-ci, procédé de préparation correspondant et utilisation associée
UY27694A1 (es) Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo.
BR112023018582A2 (pt) Processo para a síntese de derivados do ácido 5-{5-cloro-2-[(3s)-3-[(morfolin-4-il)metil]-3,4-di-hidroisoquinolina-2(1h)-carbonil]fenil}-1,2-dimetil-1h-pirrol-3-carboxílico e sua aplicação para a produção de compostos farmacêuticos
YU45896A (sh) Postupak za dobijanje epoksida
PH12022550713A1 (en) Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2- methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine